$CRIS

CURIS INC

Curis is a biotechnology company focused on developing emavusertib, an orally available small molecule inhibitor of IRAK4 and FLT3. It is evaluating the drug candidate in combination studies for relapsed or refractory primary central nervous system lymphoma and chronic lymphocytic leukemia. Its monotherapy and combination studies in acute myeloid leukemia are substantially complete. Curis holds an exclusive license to emavusertib through its collaboration with Aurigene Discovery Technologies Limited, and its other licensed Aurigene programs include candidates targeting PD1 and TIM3 immune checkpoint pathways and another immuno-oncology program. Curis makes money through royalty payments and sublicensing revenues under its license agreements. It is entitled to royalties on potential future sales of CA-170 by Aurigene and agreed royalties on product sales under the Aurigene collaboration. Curis is headquartered in Lexington, Massachusetts.

1
1
2

No SEC Form 4 filings for $CRIS in the last 30 days.

See all $CRIS insider activity →
Low

CRIS: Curis registers 320,369 shares for its 2026 Incentive Plan

Curis (CRIS) filed a Form S-8 to register 320,369 shares for its 2026 Incentive Plan, a routine equity compensation filing. The shares, with a par value of $0.01, are reserved for employees and directors, potentially increasing future supply. The filing also mentions a 1-for-20 reverse stock split effective July 2, 2026.

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

CRIS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CRIS (CURIS INC). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.

Recent CRIS coverage spans corporate actions, earnings and financial news.

What's driving CRIS

AlphAI scores every news story that mentions CRIS with an AI model for sentiment and relevance, and aggregates insider trades from CURIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CRIS

Score
$CRISHighEarnings

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMedAI 8/10Earnings

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

Curis Received Notice of Delisting

Curis (CRIS) received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price. The company plans to request a hearing to appeal, but success is not guaranteed. Curis is ineligible for a standard compliance period due to a recent reverse stock split and a one-year Panel Monitor.

$CRISMedOffering· $8.5M · proposed

CURIS INC (CRIS): Entry into a Material Definitive Agreement

CURIS INC (CRIS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 16, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the purchase and

Related tickers